This paper aims to review the guidelines on the importance given to high-density lipoprotein cholesterol (HDL-C) as a risk factor or as threshold and target level in the treatment of dyslipidemia. We developed a strategy with cholesterol-related key words to search for guidelines in the major databases. The Appraisal of Guidelines Research Evaluation (AGREE) instrument was used for the evaluation and inclusion of the guidelines. In total nine guidelines were selected. Almost all selected guidelines consider low HDL-C as a marker of an increased risk for coronary heart disease. However, only few guidelines use the level of HDL-C as a threshold or target level for the treatment of dyslipidemia. The guidelines provide only little information on the management of patients with treatment-induced low HDL-C. Instead of using total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C) we consider the use of the ratios of TC to HDL-C or LDL-C to HDL-C as a threshold as well as a target for treatment.

Keywords:
Dyslipidemia, Lipoproteins
1.
Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001–1009.
2.
Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.
3.
Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301–1307.
4.
Pedersen TR, Olsson AG, Faergeman O, et al: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453–1460.
5.
Sacks FM, Moyé LA, Davis BR, et al: Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 1998;97:1446–1452.
6.
Barr DP, Russ EM, Eder HA: Protein-lipid relationships in human plasma. Am J Med 1951;11:480–485.
7.
Castelli WP, Garrison RJ, Wilson PW, et al: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835–2838.
8.
Genest J, McNamara JR, Ordovas JM, et al: Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992;19:792–802.
9.
Rubins HB, Robins SJ, Collins D, et al: Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol 1995;75:1196–1201.
10.
Gotto AM Jr: High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 2002;144:S33–S42.
11.
Knuiman JT, Westenbrink S, van der Heyden L, et al: Determinants of total and high density lipoprotein cholesterol in boys from Finland, The Netherlands, Italy, the Philippines and Ghana with special reference to diet. Hum Nutr Clin Nutr 1983;37:237–254.
12.
Mahley RW, Palaoglu KE, Atak Z, et al: Turkish Heart Study: Lipids, lipoproteins, and apolipoproteins. J Lipid Res 1995;36:839–859.
13.
Bersot TP, Vega GL, Grundy SM, et al: Elevated hepatic lipase activity and low levels of high density lipoprotein in a normotriglyceridemic, nonobese Turkish population. J Lipid Res 1999;40:432–438.
14.
Devroey D, Betz W, Coigniez P, et al: A ‘bad responder’ to statins. Cardiology 2002;97:230–232.
15.
Devroey D, Velkeniers B, Duquet W, Betz W: Serum lipid comparison in patients treated by statins or fibrates: Existence of bad HDL-C responders to statins. Acta Cardiol 2003;58:179–184.
16.
Devroey D, Velkeniers B, Betz W, Kartounian J: The prevalence of low levels of high-density lipoprotein cholesterol among patients treated with lipid-lowering drugs. Br J Cardiol 2004;11:50–55.
17.
Cluzeau FA, Littlejohns P, Grimshaw JM, et al: Development and application of a generic methodology to assess the quality of clinical guidelines. Int J Qual Health Care 1999;11:21–28.
18.
Burgers JS, Cluzeau FA, Hanna SE, et al: Characteristics of high quality guidelines: Evaluation of 86 clinical guidelines developed in ten European countries and Canada. Int J Technol Assess Health Care 2002;18:955–964.
19.
Burgers JS, Bailey JV, Klazinga NS, et al: Inside guidelines: Comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries. Diabetes Care 2002;25:1933–1939.
20.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
21.
Wood D, De Backer G, Faergeman O, et al: Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998;140:199–270.
22.
Thomas S, Van der Weijden T, Van Drenth B, et al: NHG-Standaard Cholesterol. Huisarts Wet 1999;42:406–417.
23.
Finnish Medical Society Duodecim: Drug treatment for hyperlipidaemias; in EBM Guidelines Evidence-Based Medicine (CD-ROM). Helsinki, Duodecim Medical Publications, 2001.
24.
Scottish Intercollegiate Guidelines Network (SIGN): Secondary Prevention of Coronary Heart Disease following Myocardial Infarction. A National Clinical Guideline. Edinburgh, Sign Publications, 2000.
25.
American Association of Clinical Endocrinologists (AACE) medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis. Endocr Pract 2000;6:162–213.
26.
University of Michigan Health System (UMHS): Screening and management of lipids; in Guidelines for Clinical Care. Ann Arbor, University of Michigan, 2000.
27.
Institute for Clinical Systems improvement (ICSI): Treatment of lipid disorders in adults; in ICSI Health Care Guidelines. Bloomington, Institute for Clinical Systems Improvement, 2002.
28.
The International Task Force for Prevention of Coronary Heart Disease: The scientific background for primary and secondary prevention of coronary heart disease. Nutr Metab Cardiovasc Dis 1998;8:205–271.
29.
Rubins HB, Robins SJ, Collins D, et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410–418.
30.
Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia; safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237–1245.
31.
Assmann G, Cullen P, Schulte H: The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998;19:A2–A11.
32.
Assmann G, Schulte H, von Eckardstein A, et al: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124:S11–S20.
33.
The BIP Study Group: Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezatibrate Infarction Prevention (BIP) Study. Circulation 2000;102:21–27.
34.
Wilson PW, D’Agostino RB, Levy D, et al: Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–1847.
35.
Poulter N: The impact of micronized fenofibrate on lipid subfractions and on reaching HDL-target levels in 7,098 patients with dyslipidaemia. Br J Cardiol 1999;6:682–685.
36.
Vega GL, Grundy SM: Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med 1994;154:73–82.
37.
LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 1999;282:2340–2346.
38.
Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106:1024–1028.
39.
Gagne C, Bays HE, Weiss SR, et al: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084–1091.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.